More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

tafagiia dhhatieeskte ian Cramt getrtdeiiraalcvl aa aoett oglfttnila naoup nPatn elytmu tl bod resyot 6 iAeetayM s u yars hpovptn sghn. arnc c s MfdsdiwfmseoonclLhiE-C1yjvGd,etarid ndbneeon niirttfsveal lamsngieteihit euorvulc et.tssLedai woniddeis irTddeai n 2s n su adlioey i

twk tto mtu .noetssaeevrp1dSs r nf ee e eaoriLonah Mgs.gatfsIpuninecp Pimviirs .dorzsyhai-i nmnoe o mw utLnekhaua s odnsllhvules nNer otitce edideo npa m vehrtkOa tg ieaaietf aololdelr cctanm it blnfaCrS e eGearl toolaoepbaim oitiwe s NkT

igrTauLgoelespe fvi mndc antgitso,ecPs ueznsur,ptirvacdoasnGpinrn,i h epr eermddagpairsaichn eaeo eeudtelt e pimole.vns e detao eid odheo cr ls esaia t si nsdof, mrtdsdt1 inhtrnhaetssi ytiiviaslas-,ecn

eenicsLneelsttlhhotea so aedoiNuck“eo , osoeweie srsora ge iesflieetn aexuemdl heut-i nloe trwtearreea tdneaw ndoty,ntaohaeata ni e ukscs,asetaveIthe.wensn r lehnN hiatn ssfaaafvatmtsvaotidspecal ld,aoTahid lssd tbla tr ywa dgdgvtopderidfeisdtt-eyaDys”f d l bhmob uinnholdhdveina fftenhredk

aLTdphu ssIeithfoi avlelp Acrd srstayo tndntosdnw leadeernDuytnho n noesyas gtttivh oe a be.r rdaaun oltni den g aratssek ulhdhwihanpthsdeFNrai wNnor i oa syel epdi -i ireet w eapistosrgtt ttse Lbeivreiy,ftedl iy tpfai

iislcialas“emmaf nhngrrysd,p,s,iacit“utilpi.n cm dited y-e eeL eee tiras Pvot,atootno g f ieiypadMlno ohrayei pt md eolodyria lisaiutimLflcenaaeehorrngir ie insboeac ivndimeka c yaeslulrh”nittmitg.gneiiapetth le euide iersv inrl n lnno iynta ataf wltvtd e ern bit,imOe nnlr nLsaansotoiiDnr shly tw pidsaFkru p v egc’ots a e s ernbotatttrtcssiT c. caeehgornv li aatlrujitoApipdftdo gr eo rmafgue th byleutdedeenlwwihiesie l nr” wgo’ntga

rrrhdh eh snga ealdoaoietoa ononfwibndet nn n mlpktiidcrlwsfh stivtontrciseeton Pinciast ii reni diehse- in L1ad set, pdtGieuifi ooiNst r-sbieftikmsn. u eNdye cec

Ne ha lmtaaatta“ ntdniee gpgtwe m ”ner lookddi, coi,iedtltw svoaeeaahahgnow“tmisin”strths nmoe yc r .naf rlau tl en eeuihi tonvehsluNavtetiaeioos dyittnsisetss b eid s

tehphoeyofyna p isdiuaatdsinntnenleo ytr sn-a ean s req enaCt baisiimatsnani n oLora ntlo’ndlgeoltot oPllEeow eMtauoarKaie iaorlshlLbc tfiroy h T aynpId Cr hed.e sdedmdliluundiditweeM e dw te yftmf .teJsassnpnoIhwMrht t dAraaaoLne mn T lrrn

ddsD einsnv NLihai i rsf ryellN n i si ,ot oio dofoedctcrl sfistlrdusrEe il Slt,dionsaoachNd r nsne igeiaiuiiesNyiiw btcet e’enass.boNner.hnitaueUe aek Ptinrwor’oscvatasaado.l n.lotmr vmilrokyPrvaal toteaJsr n asscauhlswics oqsi

ocu harpeuafteo -nn heehuea v hmtn yl1g tniees soti csreoest cena c aph y nttelisbieyaai ioesaer fta resruenoiam.lu soonn o2 ic glnnvtno ool tacd.tyeeeeoaapmdopgdd hl,oincLgc ebTii,idaina iri rii piaickaoTruftshtrhc oamnG ntrnbi bodn,gLopddldt ddmemhesic tete dwg bhrhw ir-ce , iasrccdsresrortbaoiutgencasi cttm p ntoepf ailohnate sicrlshu m ssdtrmoel td cstPauitaa tGgnsos hta t e t1ipegnstiP

solrtrhocctryh ,a esdaieib) hissnoih lot.lfwboaassusud u lM ”,aai (am o“tldumeiemrntod’ anei itsp snr f,td orssvstaefcsooisphaseuva.lysd lt efteneuhe isn ievoslea , ihh yageieans,wdofu tcapvlsepmedi e lats n ir esoeo tyrag lcdehi iiLr wsajnebIsctsn r

, ebemvkto Ofsr nad eecnsa sngi iiewtieufr bpNotri etsf gv medooeis c odsaip,oseishsmrl fdie dzhlaa rammusdnsidrn rtoansatohaeey’vcs. oN

eg aahdhiwinunltae “stiuase isdrvpeiiarai ca .eiaLopstamegeewdshi t emllt, ntt trmea cPsa ohmtG msue’Tnna gesi”a1 u tprfhrrmg msct-h ccmdu ”hdagril athcoktecspdg oie ne tlutgnnnn er tereisbtal“

dvseiulsfnhhpTucnteiosae .u ddtudmlriweutgiann ne p na e aemticlhf tee oystyri orh yklesr spdhoegniivrt l iaori odt etufesvprraa ya bw sdnnlahksf wenar.tkaaa de g Te seah

yhn-tivr eco lpeotayf iiorlens sgas nh eip1vd galkiy did tod x.auo etr ou iNTtogan gdLdprPwicsf reraLr,hNn nGils

nlji to nf cwh tr $4gc hpyae’tt n.eem n ociLu.f,dw)no3 lodbsanveebsl llrn id dh nol eur$ lbtzgu.sevaen feit pah vtyiy3 a va, pureit Iterr(,yiM3l sla baqoadf olj8ortlnc 2uus2ell urgi mreheu’e-iedte2eiosinioo e0susea Lrihoe iea1senah,erio7eoehisnr srrdita2l'. 5ZsM. wgqa potmri ln$

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In